Toxins in Botanical Drugs and Plant-derived Food and Feed – from Science to Regulation: A Workshop Review

 

 Permissions and Reprints

Abstract

In September 2022, the 3rd International Workshop on pyrrolizidine alkaloids (PAs) and related phytotoxins was held on-line, entitled ʼToxins in botanical drugs and plant-derived food and feed – from science to regulationʼ. The workshop focused on new findings about the occurrence, exposure, toxicity, and risk assessment of PAs. In addition, new scientific results related to the risk assessment of alkenylbenzenes, a distinct class of herbal constituents, were presented. The presence of PAs and alkenylbenzenes in plant-derived food, feed, and herbal medicines has raised health concerns with respect to their acute and chronic toxicity but mainly related to the genotoxic and carcinogenic properties of several congeners. The compounds are natural constituents of a variety of plant families and species widely used in medicinal, food, and feed products. Their individual occurrence, levels, and toxic properties, together with the broad range of congeners present in nature, represent a striking challenge to modern toxicology. This review tries to provide an overview of the current knowledge on these compounds and indicates needs and perspectives for future research.

Publication History

Received: 17 September 2023

Accepted after revision: 23 November 2023

Article published online:
10 January 2024

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 EFSA (European Food Safety Authority). Scientific Panel on Contaminants in the Food Chain (CONTAM). Risks for human health related to the presence of pyrrolizidine alkaloids in honey, tea, herbal infusions and food supplements. EFSA J 2017; 15: 4908
  CrossrefPubMedGoogle Scholar
• 2 Bodi D, Ronczka S, Gottschalk C, Behr N, Skibba A, Wagner M, Lahrssen-Wiederholt M, Preiss-Weigert A, These A. Determination of pyrrolizidine alkaloids in tea, herbal drugs and honey. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2014; 31: 1886-1895
  CrossrefPubMedGoogle Scholar
• 3 Schrenk D, Fahrer J, Allemang A, Fu P, Lin G, Mahony C, Mulder PPJ, Peijnenburg A, Pfuhler S, Rietjens IMCM, Sachse B, Steinhoff B, These A, Troutman J, Wiesner J. Novel insights into pyrrolizidine alkaloid toxicity and implications for risk assessment: occurrence, genotoxicity, toxicokinetics, risk assessment-a workshop report. Planta Med 2022; 88: 98-117
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Clayton MJ, Davis TZ, Knoppel EL, Stegelmeier BL. Hepatotoxic plants that poison livestock. Vet Clin North Am Food Anim Pract 2020; 36: 715-723
  CrossrefPubMedGoogle Scholar
• 5 Jiao W, Wang L, Zhu L, Shen T, Shi T, Zhang P, Wang C, Chen H, Wu X, Yang T, Li Q, Hua R. Pyrrolizidine-producing weeds in tea gardens as an indicator of alkaloids in tea. Food Addit Contam Part B Surveill 2023; 16: 50-57
  CrossrefPubMedGoogle Scholar
• 6 Fu PP. Pyrrolizidine alkaloids: Metabolic activation pathways leading to liver tumor initiation. Chem Res Toxicol 2017; 30: 81-93
  CrossrefPubMedGoogle Scholar
• 7 Neuman MG, Cohen L, Opris M, Nanau RM, Hyunjin J. Hepatotoxicity of pyrrolizidine alkaloids. J Pharm Pharm Sci 2015; 18: 825-843
  CrossrefPubMedGoogle Scholar
• 8 Datta DV, Khuroo MS, Mattocks AR, Aikat BK, Chhuttani PN. Veno-occlusive disease of liver due to heliotropium plant, used as medicinal herb (report of 6 cases with review of literature). J Assoc Physicians India 1978; 26: 383-393
  PubMedGoogle Scholar
• 9 Yang M, Ma J, Ruan J, Ye Y, Fu PPC, Lin G. Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Arch Toxicol 2019; 93: 2197-2209
  CrossrefPubMedGoogle Scholar
• 10 Chan P. NTP technical report on the toxicity studies of riddelliine (CAS No. 23246–96-0) administered by gavage to F344 rats and B6C3F1 mice. Toxic Rep Ser 1993; 27: 1-D9
  PubMedGoogle Scholar
• 11 Merz KH, Schrenk D. Interim relative potency factors for the toxicological risk assessment of pyrrolizidine alkaloids in food and herbal medicines. Toxicol Lett 2016; 263: 44-57
  CrossrefPubMedGoogle Scholar
• 12 EFSA Panel on Contaminants in the Food Chain (CONTAM). Scientific opinion on pyrrolizidine alkaloids in food and feed. EFSA J 2011; 9: 2406
  CrossrefPubMedGoogle Scholar
• 13 Mulder PPJ, López P, Castellari M, Bodi D, Ronczka S, Preiss-Weigert A, These A. Occurrence of pyrrolizidine alkaloids in animal- and plant-derived food: Results of a survey across Europe. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2018; 35: 118-133
  CrossrefPubMedGoogle Scholar
• 14 Hoogenboom RLAP, Mulder PPJ, Zeilmaker MJ, van den Top HJ, Remmelink GJ, Brandon EFA, Klijnstra M, Meijer GAL, Schothorst R, Van Egmond HP. Carry-over of pyrrolizidine alkaloids from feed to milk in dairy cows. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2011; 28: 359-372
  CrossrefPubMedGoogle Scholar
• 15 Mulder PPJ, Klijnstra MD, Goselink RMA, van Vuuren AM, Cone JW, Stoopen G, Hoogenboom RLAP. Transfer of pyrrolizidine alkaloids from ragwort, common groundsel and viperʼs bugloss to milk from dairy cows. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2020; 37: 1906-1921
  CrossrefPubMedGoogle Scholar
• 16 Lamp J, Knappstein K, Walte HG, Krause T, Steinberg P, Schwake-Anduschus C. Transfer of tropane alkaloids (atropine and scopolamine) into the milk of subclinically exposed dairy cows. Food Control 2021; 126: 108056
  CrossrefPubMedGoogle Scholar
• 17 Engel AM, Klevenhusen F, Moenning JL, Numata J, Fischer-Tenhagen C, Sachse B, Schäfer B, Fry H, Kappenstein O, Pieper R. Investigations on the transfer of quinolizidine alkaloids from Lupinus angustifolius into the milk of dairy cows. J Agric Food Chem 2022; 70: 11749-11758
  CrossrefPubMedGoogle Scholar
• 18 Mulder PPJ, de Witte SL, Stoopen GM, van der Meulen J, van Wikselaar PG, Gruys E, Groot MJ, Hoogenboom RLAP. Transfer of pyrrolizidine alkaloids from various herbs to eggs and meat in laying hens. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2016; 33: 1826-1839
  CrossrefPubMedGoogle Scholar
• 19 Mulder PPJ, Mueller-Maatsch JTL, Meijer N, Bosch M, Zoet L, van der Fels-Klerx HJ. Effects of dietary exposure to plant toxins on bioaccumulation, survival, and growth of black soldier fly (Hermetia illucens) larvae and lesser mealworm (Alphitobius diaperinus). Heliyon 2023; DOI: 10.2139/ssrn.4498727. Jul 19 [Epub ahead of Print]
  CrossrefPubMedGoogle Scholar
• 20 Kaltner F, Rychlik M, Gareis M, Gottschalk C. Influence of storage on the stability of toxic pyrrolizidine alkaloids and their N-oxides in peppermint tea, hay, and honey. J Agric Food Chem 2018; 66: 5221-5228
  CrossrefPubMedGoogle Scholar
• 21 de Nijs M, Mulder PPJ, Klijnstra MD, Driehuis F, Hoogenboom RLAP. Fate of pyrrolizidine alkaloids during processing of milk of cows treated with ragwort. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2017; 34: 2212-2219
  CrossrefPubMedGoogle Scholar
• 22 Fu PP, Xia Q, Lin G, Chou MW. Pyrrolizidine alkaloids–genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004; 36: 1-55
  CrossrefPubMedGoogle Scholar
• 23 Ruan J, Yang M, Fu P, Ye Y, Lin G. Metabolic activation of pyrrolizidine alkaloids: Insights into the structural and enzymatic basis. Chem Res Toxicol 2014; 27: 1030-1039
  CrossrefPubMedGoogle Scholar
• 24 Ebmeyer J, Braeuning A, Glatt H, These A, Hessel-Pras S, Lampen A. Human CYP3A4-mediated toxification of the pyrrolizidine alkaloid lasiocarpine. Food Chem Toxicol 2019; 130: 79-88
  CrossrefPubMedGoogle Scholar
• 25 Rutz L, Gao L, Küpper JH, Schrenk D. Structure-dependent genotoxic potencies of selected pyrrolizidine alkaloids in metabolically competent HepG2 cells. Arch Toxicol 2020; 94: 4159-4172
  CrossrefPubMedGoogle Scholar
• 26 Li X, He X, Chen S, Guo X, Bryant MS, Guo L, Manjanatha MG, Zhou T, Witt KL, Mei N. Evaluation of pyrrolizidine alkaloid-induced genotoxicity using metabolically competent TK6 cell lines. Food Chem Toxicol 2020; 145: 111662
  CrossrefPubMedGoogle Scholar
• 27 Li X, Chen S, Guo X, Wu Q, Seo JE, Guo L, Manjanatha MG, Zhou T, Witt KL, Mei N. Development and application of TK6-derived cells expressing human cytochrome P450 s for genotoxicity testing. Toxicol Sci 2020; 175: 251-265
  CrossrefPubMedGoogle Scholar
• 28 Allemang A, Mahony C, Lester C, Pfuhler S. Relative potency of fifteen pyrrolizidine alkaloids to induce DNA damage as measured by micronucleus induction in HepaRG human liver cells. Food Chem Toxicol 2018; 121: 72-81
  CrossrefPubMedGoogle Scholar
• 29 Louisse J, Rijkers D, Stoopen G, Holleboom WJ, Delagrange M, Molthof E, Mulder PPJ, Hoogenboom RLAP, Audebert M, Peijnenburg AACM. Determination of genotoxic potencies of pyrrolizidine alkaloids in HepaRG cells using the γH2AX assay. Food Chem Toxicol 2019; 131: 110532
  CrossrefPubMedGoogle Scholar
• 30 Louisse J, Mulder PPJ, Gerssen A, Stoopen G, Rijkers D, van de Schans MGM, Peijnenburg AACM. Bioassay-directed analysis-based identification of relevant pyrrolizidine alkaloids. Arch Toxicol 2022; 96: 2299-2317
  CrossrefPubMedGoogle Scholar
• 31 Robinson O, Want E, Coen M, Kennedy R, van den Bosch C, Gebrehawaria Y, Kudo H, Sadiq F, Goldin RD, Hauser ML, Fenwick A, Toledano MB, Thursz MR. Hirmi Valley liver disease: A disease associated with exposure to pyrrolizidine alkaloids and DDT. J Hepatol 2014; 60: 96-102
  CrossrefPubMedGoogle Scholar
• 32 Yang M, Ruan J, Gao H, Li N, Ma J, Xue J, Ye Y, Fu PP, Wang J, Lin G. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol 2017; 91: 3913-3925
  CrossrefPubMedGoogle Scholar
• 33 He X, Xia Q, Woodling K, Lin G, Fu PP. Pyrrolizidine alkaloid-derived DNA adducts are common toxicological biomarkers of pyrrolizidine alkaloid N-oxides. J Food Drug Anal 2017; 25: 984-991
  CrossrefPubMedGoogle Scholar
• 34 Yang M, Ma J, Ruan J, Zhang C, Ye Y, Fu PPC, Lin G. Absorption difference between hepatotoxic pyrrolizidine alkaloids and their N-oxides–Mechanism and its potential toxic impact. J Ethnopharmacol 2020; 249: 112421
  CrossrefPubMedGoogle Scholar
• 35 Widjaja F, Alhejji Y, Rietjens IM. The role of kinetics as key determinant in toxicity of pyrrolizidine alkaloids and their N-oxides. Planta Med 2022; 88: 130-143
  Article in Thieme ConnectPubMedGoogle Scholar
• 36 Widjaja F, Wesseling S, Rietjens IMCM. Physiologically based kinetic modelling predicts the in vivo relative potency of riddelliine N-oxide compared to riddelliine in rat to be dose dependent. Arch Toxicol 2022; 96: 135-151
  CrossrefPubMedGoogle Scholar
• 37 Widjaja F, Alhejji Y, Yangchen J, Wesseling S, Rietjens IMCM. Physiologically-based kinetic modeling predicts similar in vivo relative potency of senecionine N-oxide for rat and human at realistic low exposure levels. Mol Nutr Food Res 2023; 67: e2200293
  CrossrefPubMedGoogle Scholar
• 38 Widjaja F, Zheng L, Wesseling S, Rietjens IMCM. Physiologically based kinetic modeling of senecionine N-oxide in rats as a new approach methodology to define the effects of dose and endpoint used on relative potency values of pyrrolizidine alkaloid N-oxides. Front Pharmacol 2023; 14: 1125146
  CrossrefPubMedGoogle Scholar
• 39 Alhejji Y, Widjaja F, Tian S, Hoekstra T, Wesseling S, Rietjens IM. The influence of dose, fraction bioactivated and endpoint used on the relative potency value of selected PA N-oxides compared to the parent PAs. Curr Res Toxic (submitted).
  PubMedGoogle Scholar
• 40 Williams L, Chou MW, Yan J, Young JF, Chan PC, Doerge DR. Toxicokinetics of riddelliine, a carcinogenic pyrrolizidine alkaloid, and metabolites in rats and mice. Toxicol Appl Pharmacol 2002; 182: 98-104
  CrossrefPubMedGoogle Scholar
• 41 Xia Q, Zhao Y, Von Tungeln LS, Doerge DR, Lin G, Cai L, Fu PP. Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity. Chem Res Toxicol 2013; 26: 1384-1396
  CrossrefPubMedGoogle Scholar
• 42 Xia Q, Zhao Y, Lin G, Beland FA, Cai L, Fu PP. Pyrrolizidine alkaloid-protein adducts: Potential non-invasive biomarkers of pyrrolizidine alkaloid-induced liver toxicity and exposure. Chem Res Toxicol 2016; 29: 1282-1292
  CrossrefPubMedGoogle Scholar
• 43 Lester C, Troutman J, Obringer C, Wehmeyer K, Stoffolano P, Karb M, Xu Y, Roe A, Carr G, Blackburn K, Mahony C. Intrinsic relative potency of a series of pyrrolizidine alkaloids characterized by rate and extent of metabolism. Food Chem Toxicol 2019; 131: 110523
  CrossrefPubMedGoogle Scholar
• 44 Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J Clin Pharmacol 2002; 42: 620-643
  CrossrefPubMedGoogle Scholar
• 45 Plaza A, Toner F, Harris J, Ottersbach P, Roper C, Mahony C. Support for regulatory assessment of percutaneous absorption of retronecine-type pyrrolizidine alkaloids through human skin. Planta Med 2022; 88: 144-151
  Article in Thieme ConnectPubMedGoogle Scholar
• 46 EFSA (European Food Safety Authority). Guidance on dermal absorption. EFSA J 2017; 15: 4873
  PubMedGoogle Scholar
• 47 OECD (Organisation for Economic Co-operation and Development). Test No. 428: Skin Absorption: In Vitro Method. OECD Guidelines for the Testing of Chemicals, Section 4. Paris: OECD Publishing; 2004
  Google Scholar
• 48 OECD (Organisation for Economic Co-operation and Development). Guidance Document for the Conduct of Skin Absorption Studies, OECD Series on Testing and Assessment, No. 28. Paris: OECD Publishing,; 2004
  Google Scholar
• 49 SCCS (Scientific Committee on Consumer Safety). Basic criteria for the assessment of dermal absorption of cosmetic ingredients, 22 June 2010. Accessed May 13, 2023 at: https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_s_002.pdf
  PubMedGoogle Scholar
• 50 HMPC (Committee on Herbal Medicinal Products). Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs), EMA/HMPC/893108/2011 Rev. 1, 07.07.2021. Accessed May 04, 2023 at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf
  PubMedGoogle Scholar
• 51 BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte). Bekanntmachung zur Prüfung des Gehalts an Pyrrolizidinalkaloiden zur Sicherstellung der Qualität und Unbedenklichkeit von Arzneimitteln, die pflanzliche Stoffe bzw. pflanzliche Zubereitungen oder homöopathische Zubereitungen aus pflanzlichen Ausgangsstoffen als Wirkstoffe enthalten. BfArM Bekanntmachung 01.03.2016 (in German). Accessed April 26, 2023 at: https://www.bfarm.de/SharedDocs/Bekanntmachungen/DE/Arzneimittel/besTherap/bm-besTherap-20160301-pa-pdf.html
  PubMedGoogle Scholar
• 52 BfR (Bundesinstitut für Risikobewertung). Aktualisierte Risikobewertung zu Gehalten an 1, 2-ungesättigten Pyrrolizidinalkaloiden (PA) in Lebensmitteln Juni 2018 (Stellungnahme Nr. 020/2018) 06.2018 (in German). Accessed May 13, 2023 at: https://www.bfr.bund.de/cm/343/aktualisierte-risikobewertung-zu-gehalten-an-1-2-ungesaettigten-pyrrolizidinalkaloiden-pa-in-lebensmitteln.pdf
  PubMedGoogle Scholar
• 53 BfR (Bundesinstitut für Risikobewertung). Bestimmung von Pyrrolizidinalkaloiden (PA) in Pflanzenmaterial mittels SPE-LC-MS/MS (BfR-PA-Tee-2.0/2014) 10.2014 (in German). Accessed May 27, 2023 at: https://www.bfr.bund.de/cm/343/bestimmung-von-pyrrolizidinalkaloiden.pdf
  PubMedGoogle Scholar
• 54 European Pharmacopoeia. Vol. 10.6. Contaminant pyrrolizidine alkaloids, Council of Europe 01/2022: Ph. Eur. 2.8.26. Accessed December 07, 2023 at: https://pheur.edqm.eu/home
  PubMedGoogle Scholar
• 55 Lin G, Wang JY, Li N, Li M, Gao H, Ji Y, Zhang F, Wang H, Zhou Y, Ye Y, Hong XX, Zheng J. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 2011; 54: 666-673
  CrossrefPubMedGoogle Scholar
• 56 Mohabbat O, Younos MS, Merzad AA, Srivastava RN, Sediq GG, Aram GN. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. The Lancet 1976; 308: 269-271
  CrossrefPubMedGoogle Scholar
• 57 He Y, Long Y, Zhang C, Ma J, Ke C, Tang C, Ye Y, Lin G. Dietary alcohol exacerbates the hepatotoxicity induced by pyrrolizidine alkaloids: Hazard from food contamination. J Hazard Mater 2022; 424: 127706
  CrossrefPubMedGoogle Scholar
• 58 He Y, Zhu L, Ma J, Lin G. Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids. Arch Toxicol 2021; 95: 1917-1942
  CrossrefPubMedGoogle Scholar
• 59 He Y, Lian W, Ding L, Fan X, Ma J, Zhang QY, Ding X, Lin G. Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450 s and blood transport of reactive metabolites. Arch Toxicol 2021; 95: 103-116
  CrossrefPubMedGoogle Scholar
• 60 He Y, Ma J, Fan X, Ding L, Ding X, Zhang QY, Lin G. The key role of gut–liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity. Acta Pharm Sin B 2021; 11: 3820-3835
  CrossrefPubMedGoogle Scholar
• 61 Chen L, Mulder PPJ, Louisse J, Peijnenburg A, Wesseling S, Rietjens I. Risk assessment for pyrrolizidine alkaloids detected in (herbal) teas and plant food supplements. Regul Toxicol Pharmacol 2017; 86: 292-302
  CrossrefPubMedGoogle Scholar
• 62 Schrenk D, Gao L, Lin G, Mahony C, Mulder PPJ, Peijnenburg A, Pfuhler S, Rietjens IMCM, Rutz L, Steinhoff B, These A. Pyrrolizidine alkaloids in food and phytomedicine: Occurrence, exposure, toxicity, mechanisms, and risk assessment – A review. Food Chem Toxicol 2020; 136: 111107
  CrossrefPubMedGoogle Scholar
• 63 Herzog N, Katzenberger N, Martin F, Schmidtke KU, Küpper JH. Generation of cytochrome P450 3A4-overexpressing HepG2 cell clones for standardization of hepatocellular testosterone 6β-hydroxylation activity. J Cell Biotechnol 2015; 1: 15-26
  CrossrefPubMedGoogle Scholar
• 64 Haas M, Wirachowski K, Thibol L, Kupper JH, Schrenk D, Fahrer J. Potency ranking of pyrrolizidine alkaloids in metabolically competent human liver cancer cells and primary human hepatocytes using a genotoxicity test battery. Arch Toxicol 2023; 97: 1413-1428
  CrossrefPubMedGoogle Scholar
• 65 Geburek I, Schrenk D, These A. In vitro biotransformation of pyrrolizidine alkaloids in different species: Part II-identification and quantitative assessment of the metabolite profile of six structurally different pyrrolizidine alkaloids. Arch Toxicol 2020; 94: 3759-3774
  CrossrefPubMedGoogle Scholar
• 66 Geburek I, Preiss-Weigert A, Lahrssen-Wiederholt M, Schrenk D, These A. In vitro metabolism of pyrrolizidine alkaloids – Metabolic degradation and GSH conjugate formation of different structure types. Food Chem Toxicol 2020; 135: 110868
  CrossrefPubMedGoogle Scholar
• 67 Geburek I, Rutz L, Gao L, Küpper JH, These A, Schrenk D. Metabolic pattern of hepatotoxic pyrrolizidine alkaloids in liver cells. Chem Res Toxicol 2021; 34: 1101-1113
  CrossrefPubMedGoogle Scholar
• 68 Shimshoni JA, Barel S, Mulder PPJ. Comparative risk assessment of three native Heliotropium species in Israel. Molecules 2021; 26: 689
  CrossrefPubMedGoogle Scholar
• 69 Chen L, Zhang Q, Yi Z, Chen Y, Xiao W, Su D, Shi W. Risk assessment of (herbal) teas containing pyrrolizidine alkaloids (PAs) based on margin of exposure approach and Relative Potency (REP) Factors. Foods 2022; 11: 2946
  CrossrefPubMedGoogle Scholar
• 70 Al-Subeihi AAA, Spenkelink B, Punt A, Boersma MG, van Bladeren PJ, Rietjens IMCM. Physiologically based kinetic modeling of bioactivation and detoxification of the alkenylbenzene methyleugenol in human as compared with rat. Toxicol Appl Pharmacol 2012; 260: 271-284
  CrossrefPubMedGoogle Scholar
• 71 Martati E, Boersma MG, Spenkelink A, Khadka DB, van Bladeren PJ, Rietjens IMCM, Punt A. Physiologically based biokinetic (PBBK) modeling of safrole bioactivation and detoxification in humans as compared with rats. Toxicol Sci 2012; 128: 301-316
  CrossrefPubMedGoogle Scholar
• 72 Punt A, Paini A, Boersma MG, Freidig AP, Delatour T, Scholz G, Schilter B, van Bladeren P, Rietjens IMCM. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol Sci 2009; 110: 255-269
  CrossrefPubMedGoogle Scholar
• 73 van den Berg SJPL, Punt A, Soffers AEMF, Vervoort J, Ngeleja S, Spenkelink B, Rietjens IMCM. Physiologically based kinetic models for the alkenylbenzene elemicin in rat and human and possible implications for risk assessment. Chem Res Toxicol 2012; 25: 2352-2367
  CrossrefPubMedGoogle Scholar
• 74 Alhusainy W, van den Berg SJPL, Paini A, Campana A, Asselman M, Spenkelink A, Punt A, Scholz G, Schilter B, Adams TB, van Bladeren PJ, Rietjens IMCM. Matrix modulation of the bioactivation of estragole by constituents of different alkenylbenzene-containing herbs and spices and physiologically based biokinetic modeling of possible in vivo effects. Toxicol Sci 2012; 129: 174-187
  CrossrefPubMedGoogle Scholar
• 75 Alhusainy W, Paini A, van den Berg JHJ, Punt A, Scholz G, Schilter B. In vivo validation and physiologically based biokinetic modeling of the inhibition of SULT-mediated estragole DNA adduct formation in the liver of male Sprague-Dawley rats by the basil flavonoid nevadensin. Mol Nutr Food Res 2013; 57: 1969-1978
  CrossrefPubMedGoogle Scholar
• 76 Rietjens IM, Cohen SM, Fukushima S, Gooderham NJ, Hecht S, Marnett LJ, Smith RL, Adams TB, Bastaki M, Harman CG, Taylor SV. Impact of structural and metabolic variations on the toxicity and carcinogenicity of hydroxy- and alkoxy-substituted allyl and propenylbenzenes. Chem Res Toxicol 2014; 27: 1092-1103
  CrossrefPubMedGoogle Scholar
• 77 Eisenreich A, Götz ME, Sachse B, Monien BH, Herrmann K, Schäfer B. Alkenylbenzenes in foods: Aspects impeding the evaluation of adverse health effects. Foods 2021; 10: 2139
  CrossrefPubMedGoogle Scholar
• 78 Homburger F, Kelley jr. T, Friedler G, Russfield AB. Toxic and possible carcinogenic effects of 4-allyl-1, 2- methylenedioxybenzene (safrole) in rats on deficient diets. Med Exp Int J Exp Med 1961; 4: 1-11
  PubMedGoogle Scholar
• 79 EC (European Commission). Regulation No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Off J Europ Union 31.12.2008. Accessed May 12, 2023 at: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:354:0034:0050:en:PDF
  PubMedGoogle Scholar
• 80 SCF (Scientific Committee on Food). Opinion of the Scientific Committee on Food on estragole (1-allyl-4-methoxybenzene). SCF/CS/FLAV/FLAVOUR/6 ADD 2 Final 26 September 2001. Accessed April 04, 2023 at: https://ec.europa.eu/food/system/files/2016-10/fs_food-improvement-agents_flavourings-out104.pdf
  PubMedGoogle Scholar
• 81 EMA (European Medicines Agency). Committee on Herbal Medicinal Products (HMPC). Public statement on the use of herbal medicinal products containing estragole. EMA/HMPC/137212/2005 Rev 1, 22 September 2021. (Publication March 1st, 2022). Accessed December 07, 2023 at: https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-revised-public-statement-use-herbal-medicinal-products-containing-estragole-emahmpc1372122005-rev-1-2nd-draft_en.pdf
  PubMedGoogle Scholar
• 82 EMEA (European Medicines Agency). Herbal Medicinal Products Working Party (HMPWP): Position paper on the use of herbal medicinal products containing asarone, 2003. EMEA/HMPWP/41/03 Final. Accessed March 16, 2023 at: https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-30-june-and-1-july-2003_en.pdf
  PubMedGoogle Scholar
• 83 EMEA (European Medicines Agency). Herbal Medicinal Products Committee (HMPC). Public statement on the use of herbal medicinal products containing asarone, 2005. EMEA/HMPC/139215/2005. Accessed May 29, 2023 at: https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-methyleugenol_en.pdf
  PubMedGoogle Scholar
• 84 EMEA (European Medicines Agency). Herbal Medicinal Products Committee (HMPC). Public Statement on the use of herbal medicinal products containing methyleugenol, 2005. EMEA/HMPC/138363/2005. Accessed May 12, 2023 at: https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-methyleugenol_en.pdf
  PubMedGoogle Scholar
• 85 EMEA (European Medicines Agency). Herbal Medicinal Products Committee (HMPC). Public Statement on the use of herbal medicinal products containing estragole, 2005. EMEA/HMPC/137212/2005. Accessed April 25, 2023 at: https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-estragole_en.pdf
  PubMedGoogle Scholar
• 86 Bristol DW. NTP 3-month toxicity studies of estragole (CAS No. 140–67-0) administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 2011; 82: 1-111
  PubMedGoogle Scholar
• 87 EFSA Scientific Cooperation (ESCO) Report. Advice on the guidance document for the safety assessment of botanicals and botanical preparations intended for use as food supplements, based on real case studies. EFSA J 2009; 7: 280
  PubMedGoogle Scholar
• 88 EMA (European Medicines Agency). Committee on Herbal Medicinal Products (HMPC) Public statement on the use of herbal medicinal products containing estragole. EMA/HMPC/137212/2005 Rev 1 (draft published 2014). Accessed December 07, 2023 at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-estragole_en.pdf
  PubMedGoogle Scholar
• 89 EMA (European Medicines Agency). Committee for Human Medicinal Products. ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk – Step 5 (EMA/CHMP/ICH/83812/2013), 25 August 2015. Accessed December 07, 2023 at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf
  PubMedGoogle Scholar
• 90 EMA (European Medicines Agency). Co-ordination Group for Mutual Recognition and Decentralised Procedures (CMDh). Report from the CMDh meeting held on 22–23 February 2022 (EMA/CMDh/78976/2022), 2 March 2022. Accessed December 07, 2023 at: https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-21-24-february-2022_en.pdf
  PubMedGoogle Scholar
• 91 EMA (European Medicines Agency). Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus Draft – Revision July 2022 (EMEA/HMPC/372841/2016). Accessed December 07, 2023 at: https://www.ema.europa.eu/en/medicines/herbal/foeniculi-amari-fructus
  PubMedGoogle Scholar
• 92 EMA (European Medicines Agency). Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus Draft – Revision July 2022EMEA/HMPC/372839/2016. Accessed December 07, 2023 at: https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
  PubMedGoogle Scholar
• 93 EMA (European Medicines Agency). Committee on Herbal Medicinal Products (HMPC) Public statement on Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum Draft – EMA/HMPC/522456/2021. Accessed December 07, 2023 at: https://www.ema.europa.eu/en/medicines/herbal/foeniculi-amari-fructus-aetheroleum
  PubMedGoogle Scholar
• 94 Pank F, Schneider E, Krüger H. Possibilities and limitations of estragole content reduction of fennel (Foeniculum vulgare Mill.) and its preparations. Zeitschr Arzn Gewürzpfl 2003; 8: 165-172
  PubMedGoogle Scholar
• 95 EC (European Commission). Directorate-General for Health and Food Safety, Food and Feed Safety, Innovation E1 – Food information and composition ref. Ares (2022)5233398-19/07/2022. Accessed December 07, 2023 at: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-10-european-innovation-ecosystems_horizon-2021-2022_en.pdf
  PubMedGoogle Scholar
• 96 Smith RL, Adams TB, Doull J, Feron VJ, Goodman JI, Marnett LJ, Portoghese PS, Waddell WJ, Wagner BM, Rogers AE, Caldwell J, Sipes IG. Safety assessment of allylalkoxybenzene derivatives used as flavouring substances – methyl eugenol and estragole. Food Chem Toxicol 2002; 40: 851-870
  CrossrefPubMedGoogle Scholar
• 97 Anthony A, Caldwell J, Hutt AJ, Smith RL. Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1′-hydroxyestragole. Food Chem Toxicol 1987; 25: 799-806
  CrossrefPubMedGoogle Scholar
• 98 Guenthner TM, Luo G. Investigation of the role of the 2′,3′-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs. Toxicology 2001; 160: 47-58
  CrossrefPubMedGoogle Scholar
• 99 Jeurissen SM, Punt A, Boersma MG, Bogaards JJP, Yiannis CF, Schilter B, van Bladeren PJ, Cnubben NHP, Rietjens IMCM. Human cytochrome P450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes. Chem Res Toxicol 2007; 20: 798-806
  CrossrefPubMedGoogle Scholar
• 100 Herrmann K, Engst W, Appel KE, Monien BH, Glatt H. Identification of human and murine sulfotransferases able to activate hydroxylated metabolites of methyleugenol to mutagens in Salmonella typhimurium and detection of associated DNA adducts using UPLC-MS/MS methods. Mutagenesis 2012; 27: 453-462
  CrossrefPubMedGoogle Scholar
• 101 Suzuki Y, Umemura T, Ishii Y, Hibi D, Inoue T, Jin M, Sakai H, Kodama Y, Nohmi T, Yanai T, Nishikawa A, Ogawa K. Possible involvement of sulfotransferase 1A1 in estragole-induced DNA modification and carcinogenesis in the livers of female mice. Mutat Res 2012; 749: 23-28
  CrossrefPubMedGoogle Scholar
• 102 Ishii Y, Suzuki Y, Hibi D, Jin M, Fukuhara K, Umemura T, Nishikawa A. Detection and quantification of specific DNA adducts by liquid chromatography-tandem mass spectrometry in the livers of rats given estragole at the carcinogenic dose. Chem Res Toxicol 2011; 24: 532-541
  CrossrefPubMedGoogle Scholar
• 103 Punt A, Delatour T, Scholz G, Schilter B, van Bladeren PJ, Rietjens IMCM. Tandem mass spectrometry analysis of N2-(trans-Isoestragol-3′-yl)-2′-deoxyguanosine as a strategy to study species differences in sulfotransferase conversion of the proximate carcinogen 1′-hydroxyestragole. Chem Res Toxicol 2007; 20: 991-998
  CrossrefPubMedGoogle Scholar
• 104 Schulte-Hubbert R, Kupper JH, Thomas AD, Schrenk D. Estragole: DNA adduct formation in primary rat hepatocytes and genotoxic potential in HepG2-CYP1A2 cells. Toxicology 2020; 444: 152566
  CrossrefPubMedGoogle Scholar
• 105 Yang X, Feng Y, Zhang Z, Wang H, Li W, Wang DO, Peng Y, Zheng J. In vitro and in vivo evidence for RNA adduction resulting from metabolic activation of methyleugenol. J Agric Food Chem 2020; 68: 15134-15141
  CrossrefPubMedGoogle Scholar
• 106 Carlsson MJ, Vollmer AS, Demuth P, Heylmann D, Reich D, Quarz C, Rasenberger B, Nikolova T, Hofmann TG, Christmann M, Fuhlbrueck JA, Stegmüller S, Richling E, Cartus AT, Fahrer J. P53 triggers mitochondrial apoptosis following DNA damage-dependent replication stress by the hepatotoxin methyleugenol. Cell Death Dis 2022; 13: 1009
  CrossrefPubMedGoogle Scholar
• 107 Thomas AD, Fahrer J, Johnson GE, Kaina B. Theoretical considerations for thresholds in chemical carcinogenesis. Mutat Res Rev Mutat Res 2015; 765: 56-67
  CrossrefPubMedGoogle Scholar
• 108 Doak SH, Jenkins GJ, Johnson GE, Quick E, Parry EM, Parry JM. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res 2007; 67: 3904-3911
  CrossrefPubMedGoogle Scholar
• 109 Fahrer J, Frisch J, Nagel G, Kraus A, Dörsam B, Thomas AD, Reißig S, Waisman A, Kaina B. DNA repair by MGMT, but not AAG, causes a threshold in alkylation-induced colorectal carcinogenesis. Carcinogenesis 2015; 36: 1235-1244
  CrossrefPubMedGoogle Scholar
• 110 Kraus A, McKeague M, Seiwert N, Nagel G, Geisen SM, Ziegler N, Trantakis IA, Kaina B, Thomas AD, Sturla SJ, Fahrer J. Immunological and mass spectrometry-based approaches to determine thresholds of the mutagenic DNA adduct O(6)-methylguanine in vivo. Arch Toxicol 2019; 93: 559-572
  CrossrefPubMedGoogle Scholar
• 111 Thomas AD, Jenkins GJ, Kaina B, Bodger OG, Tomaszowski K, Lewis PD, Doak SH. Influence of DNA repair on nonlinear dose-responses for mutation. Toxicol Sci 2013; 132: 87-95
  CrossrefPubMedGoogle Scholar